Current label evidence
Semaglutide labels report grouped local reactions, not a burning rate
The June 2026 Wegovy label reports grouped injection-site reactions in 1.4% of treated adults and 1% of placebo-treated adults in weight-reduction trials; the group includes itching, redness, inflammation, firmness, and irritation. The June 2026 Ozempic label reports grouped injection-site reactions such as discomfort or redness in 0.2% of treated patients in placebo-controlled trials. Neither label isolates burning or stinging or establishes an expected onset, severity, size, or duration for that sensation.
- Do not call 1.4% or 0.2% a burning rate; each percentage describes a product- and trial-specific grouped local-reaction category.
- Do not compare the grouped percentages as proof that one semaglutide product is less likely to burn because products, presentations, indications, populations, and trial definitions differ.
- A trial rate cannot determine whether one symptom reflects skin irritation, allergy, infection, tissue injury, a device or supply issue, or another cause.
Symptom pattern
A brief sting and a worsening painful reaction need different review
A short localized sting can look very different from persistent burning with expanding redness, increasing warmth, severe pain, swelling, drainage, fever, blistering, or skin-color change. Current semaglutide labels warn about serious hypersensitivity reactions, including anaphylaxis and angioedema. MedlinePlus lists rash, itching, fainting or dizziness, swelling of the eyes, face, mouth, tongue, or throat, and difficulty breathing or swallowing among symptoms that require immediate medical attention. A symptom list or photo cannot diagnose allergy, cellulitis, abscess, contact irritation, or tissue injury.
- Document when the sensation began, how long it lasted, whether it recurs, whether the border is spreading, and what local or whole-body symptoms occurred.
- Tell the clinician about prior injection reactions, allergies, eczema or other skin disease, diabetes, immune suppression, circulation problems, and medicines that affect bleeding or immunity.
- Persistent, recurrent, worsening, spreading, unusually painful, or treatment-limiting burning deserves clinical review even when a forum describes it as normal.
Product and route identity
Match the symptom to the exact semaglutide product and presentation
Wegovy and Ozempic injections contain semaglutide, but they have product-specific presentations and instructions. Wegovy also has a labeled once-daily oral tablet, which cannot cause an injection-site symptom. A review should identify the exact brand or compounded prescription, route, device or vial, concentration, dispensing pharmacy, supplies, and storage history before applying label evidence. Follow the instructions supplied with the exact prescribed product rather than turning a symptom page into a substitute injection tutorial.
- Preserve the product name, route, strength or concentration, package or patient label, refill or lot details, device or vial, needle and supplies, pharmacy, shipment, and storage history.
- Report whether the skin was already red, swollen, bruised, scarred, hardened, infected, recently shaved, or exposed to a new alcohol prep, adhesive, bandage, cleanser, lotion, or topical medicine.
- Do not repeat, increase, split, retime, change products, or use another injection as a test without guidance from the responsible prescriber or pharmacist.
Compounded-product boundary
Branded reaction rates do not transfer to compounded semaglutide
Wegovy and Ozempic are FDA-approved finished drug products with manufacturer labels for specific presentations. A patient-specific compounded semaglutide prescription is not FDA-approved as a finished drug product and may differ in concentration, inactive ingredients, container, supplies, storage directions, and beyond-use date. Branded trial percentages can provide context, but they cannot validate a compounded preparation, establish its reaction rate, or explain why one injection site burns.
- For a compounded product, preserve the patient label, dispensing-pharmacy details, active ingredient, concentration, inactive ingredients when available, refill or lot information, storage history, and adverse-event contact.
- Ask the pharmacy about a changed concentration or label, damaged package, delayed or warm shipment, cloudy or discolored solution, particles, uncertain storage, or a different needle or supply before another use decision.
- Avoid research-use vials, counterfeit pens, unlabeled mixtures, no-prescription sellers, copied syringe conversions, and claims that burning proves potency or absorption.
Escalation
Separate prescriber follow-up from infection and allergy emergencies
A mild stable symptom may be appropriate for prescriber follow-up, but rapidly spreading redness or swelling, severe or escalating pain, pus, red streaks, fever, blistering, darkening, skin breakdown, or feeling acutely unwell can require prompt local assessment. Widespread hives, wheezing, breathing difficulty, throat tightness, facial or tongue swelling, fainting, confusion, or rapidly developing whole-body symptoms are not routine local reactions and can require emergency care.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or rapidly developing widespread hives or swelling.
- Seek prompt local assessment for rapid spread, severe or disproportionate pain, pus or drainage, red streaks, fever or chills, blistering, darkening, or skin breakdown.
- Contact the prescriber for persistent, recurrent, worsening, spreading, or treatment-limiting burning and before another injection or product decision.